.png)
Md-size Pharmaceutical
Market Access, HEOR, Clinical, RWE
Phase III / Pre-Launch
Rare Disease
Subscribe to our newsletter to receive the latest case studies.
Md-size Pharmaceutical
Market Access, HEOR, Clinical, RWE
Phase III / Pre-Launch
Rare Disease
A mid-size pharmaceutical company was preparing for Phase III completion and pre-launch activities in a rare disease.
The team faced challenges engaging patients and providers across U.S. and ex-U.S. markets, and prior recruitment efforts had fallen short.
With HTA negotiations and real-world research underway, the client needed a coordinated, scalable engagement approach to support participation, communication, and dissemination.
1. Conducted interviews with internal stakeholders, patient advocacy organizations, and country-level KOLs to identify engagement barriers and opportunities.
2. Reviewed secondary sources to benchmark best practices in recruitment, communication, and collaboration pathways.
3. Synthesized findings into a practical, country-adaptable engagement strategy aligned to clinical and access objectives.
4. Developed tactical playbooks to support recruitment, partnership building, and dissemination planning.
Turn engagement into a structured, measurable driver of launch readiness.
“Alkemi translated engagement insights into a practical strategy that strengthened recruitment and improved our pre-launch readiness.” - Senior Director, Market Access
Prioritized high-impact tactics that increased patient and HCP engagement.
Enabled new patient-led communication mechanisms to support information sharing.
Contributed to successful execution of a large observational study with improved participation and timely dissemination.